Dapagliflozin aids glycemic control in type 2 diabetes

March 20, 2012
Dapagliflozin aids glycemic control in type 2 diabetes

(HealthDay) -- For patients with inadequately controlled type 2 diabetes, treatment with dapagliflozin is associated with improved glycemic control, stabilized insulin dosing, and weight reductions, according to research published in the March 20 issue of the Annals of Internal Medicine.

To evaluate the efficacy and safety of dapagliflozin, John P.H. Wilding, D.M., of University Hospital Aintree in Liverpool, U.K., and associates randomly assigned 800 patients with inadequately controlled , receiving at least 30 units of insulin daily, with or without up to two oral antidiabetic drugs, to receive a daily dose of dapagliflozin (2.5, 5, or 10 mg) or placebo for 48 weeks.

After 24 weeks, the researchers found that patients taking dapagliflozin had a 0.79 to 0.96 percent decrease in mean hemoglobin A1c, compared with a 0.39 percent decrease with placebo. The daily insulin dose decreased by 0.63 units with dapagliflozin compared with an increase of 5.65 units in the . Dapagliflozin was associated with a decrease of 0.92 to 1.61 kg in body weight, compared with an increase of 0.43 kg in the placebo group. At 48 weeks, these effects were maintained. Patients in the pooled dapagliflozin groups had a higher rate of hypoglycemic episodes compared with the placebo group (56.6 versus 51.8 percent).

"Dapagliflozin improves glycemic control, stabilizes insulin dosing, and reduces weight without increasing major in patients with inadequately controlled ," the authors write.

The study was funded by AstraZeneca and Bristol-Myers Squibb, co-developers of dapagliflozin. Several of the authors are employees of AstraZeneca.

Explore further: New type 2 diabetes drug helps lower blood sugar: study

More information: Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Related Stories

Recommended for you

How does friendly fire happen in the pancreas?

October 21, 2016

In type 1 diabetes, the body attacks its own insulin-producing cells. Scientists at Helmholtz Zentrum München, partner in the German Center for Diabetes Research, and their colleagues at Technical University of Munich have ...

Diabetes opens floodgates to fructose

October 11, 2016

Fructose, once seen as diabetics' alternative to glucose, is fast-tracked to the liver in diabetic mice and contributes to metabolic diseases, according to new research from Harvard University.

Type 2 diabetes and obesity—what do we really know?

October 6, 2016

Social and economic factors have led to a dramatic rise in type 2 diabetes and obesity around the world. In a review in Science, Mark McCarthy, professor at the University of Oxford, UK, and Paul Franks, professor at Lund ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.